© 2022 MJH Life Sciences and Center for Biosimilars®. All rights reserved.
© 2022 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
IP Attorneys Propose a New Biosimilar Pathway in Case of ACA Repeal
Opinion: Purple Book Patent Listings Are Only a First Step
Julie Reed On How the Biosimilars Forum is Helping FDA Catch Up on Biosimilar Inspections
Contributor: Interchangeability Is a Dispensing Issue, Not a Prescribing One
Americans Say Drug Costs Are Too High, and They Are Right
Column: India Struggles to Meet International Biologics Standards
Opinion: Biosimilars Offer Savings and Access for US Patients
Biosimilars and Women's Health: Realizing the Potential